{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T18:07:37Z","timestamp":1719943657639},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Theramyt Novobiologics"},{"name":"Zumutor Biologics"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.biologicals.2017.05.002","type":"journal-article","created":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T09:16:25Z","timestamp":1496049385000},"page":"82-91","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Microbial expression of Exendin-4 analog and its efficacy in mice model"],"prefix":"10.1016","volume":"48","author":[{"given":"Bhargav Prasad","family":"Kodaganti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavithra","family":"Mukunda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravinkumar","family":"Dakshinamurthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogendra","family":"Manjunath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharath Ravindra","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veeresha","family":"Kamanagowda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bairavabalakumar","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amol","family":"Maliwalave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Unnikrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sathyabalan","family":"Murugesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Halan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maloy","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunit","family":"Maity","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2017.05.002_bib1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd1723","article-title":"Type 2 diabetes market","volume":"4","author":"Gershell","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.biologicals.2017.05.002_bib2","series-title":"Type 2 diabetes market set to hit $39bn by 2021","author":"Tyer","year":"2015"},{"key":"10.1016\/j.biologicals.2017.05.002_bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0140-6736(11)60207-9","article-title":"Management of type 2 diabetes: new and future developments in treatment","volume":"378","author":"Tahrani","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.biologicals.2017.05.002_bib4","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1016\/j.clinthera.2012.12.012","article-title":"New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity","volume":"35","author":"Taylor","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.biologicals.2017.05.002_bib5","series-title":"Type 2 Diabetes-Japan drug forecast and market analysis to 2022","year":"2013"},{"key":"10.1016\/j.biologicals.2017.05.002_bib6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/08998280.2006.11928181","article-title":"Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus","volume":"19","author":"Bond","year":"2006","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.biologicals.2017.05.002_bib7","doi-asserted-by":"crossref","first-page":"e20443","DOI":"10.1371\/journal.pone.0020443","article-title":"Exendin-4 improves blood glucose control in both young and aging normal non-diabetic mice, possible contribution of beta cell independent effects","volume":"6","author":"Fan","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.biologicals.2017.05.002_bib8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.toxicon.2010.12.016","article-title":"The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent","volume":"59","author":"Furman","year":"2012","journal-title":"Toxicon"},{"key":"10.1016\/j.biologicals.2017.05.002_bib9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.clinthera.2006.05.006","article-title":"Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus","volume":"28","author":"Iltz","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.biologicals.2017.05.002_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/17460441.2013.741580","article-title":"Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1","volume":"8","author":"Parkes","year":"2013","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.biologicals.2017.05.002_bib11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s13300-013-0046-7","article-title":"Physician preferences for extra-glycemic effects of type 2 diabetes treatments","volume":"4","author":"Poulos","year":"2013","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.biologicals.2017.05.002_bib12","doi-asserted-by":"crossref","first-page":"470851","DOI":"10.1155\/2012\/470851","article-title":"Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor","volume":"2012","author":"Willard","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.biologicals.2017.05.002_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pep.2004.10.014","article-title":"Expression and purification of exendin-4, a GLP-1 receptor agonist, in Escherichia coli","volume":"41","author":"Yin","year":"2005","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.biologicals.2017.05.002_bib14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fmicb.2014.00172","article-title":"Recombinant protein expression in Escherichia coli: advances and challenges","volume":"5","author":"Rosano","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.biologicals.2017.05.002_bib15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00253-002-1158-6","article-title":"Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems","volume":"60","author":"Terpe","year":"2003","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.biologicals.2017.05.002_bib16","first-page":"581093","article-title":"Several affinity tags commonly used in chromatographic purification","volume":"2013","author":"Zhao","year":"2013","journal-title":"J\u00a0Anal Methods Chem"},{"key":"10.1016\/j.biologicals.2017.05.002_bib17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0165-022X(01)00206-8","article-title":"Twenty-five years of immobilized metal ion affinity chromatography: past, present and future","volume":"49","author":"Chaga","year":"2001","journal-title":"J\u00a0Biochem Biophys Methods"},{"key":"10.1016\/j.biologicals.2017.05.002_bib18","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.biologicals.2017.05.002_bib19","first-page":"544","article-title":"Peptide mapping analysis of Exenatide by LC-MS spectrometry","volume":"5","author":"Fu","year":"2009","journal-title":"West China J Pharm Sci"},{"key":"10.1016\/j.biologicals.2017.05.002_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.colsurfb.2013.08.048","article-title":"Preparation of uniform-sized exenatide-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency and bio-stability","volume":"112","author":"Qi","year":"2013","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.biologicals.2017.05.002_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jpha.2012.12.007","article-title":"Ultra-high-performance liquid chromatography for the determination of exenatide in monkey plasma by tandem quadrupole mass spectrometry","volume":"3","author":"Zhang","year":"2013","journal-title":"J\u00a0Pharm Analysis"},{"key":"10.1016\/j.biologicals.2017.05.002_bib22","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1002\/cbic.200500152","article-title":"Circular dichroism of designed peptide helices and beta-hairpins: analysis of Trp- and Tyr-rich peptides","volume":"6","author":"Mahalakshmi","year":"2005","journal-title":"Chembiochem"},{"key":"10.1016\/j.biologicals.2017.05.002_bib23","first-page":"e159","article-title":"Glucose tolerance test in mice","volume":"101","author":"Zhang","year":"2011","journal-title":"Bio-protocol"},{"key":"10.1016\/j.biologicals.2017.05.002_bib24","doi-asserted-by":"crossref","first-page":"24834","DOI":"10.1038\/srep24834","article-title":"Glucose becomes one of the worst carbon sources for E.coli on poor nitrogen sources due to suboptimal levels of cAMP","volume":"6","author":"Bren","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.biologicals.2017.05.002_bib25","author":"Monod","year":"1941"},{"key":"10.1016\/j.biologicals.2017.05.002_bib26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1186\/1756-0500-7-671","article-title":"Evaluation of pre-induction temperature, cell growth at induction and IPTG concentration on the expression of a leptospiral protein in E. coli using shaking flasks and microbioreactor","volume":"7","author":"Larentis","year":"2014","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.biologicals.2017.05.002_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1385\/ABAB:135:1:59","article-title":"Sequential and simultaneous statistical optimization by dynamic design of experiment for peptide overexpression in recombinant Escherichia coli","volume":"135","author":"Lee","year":"2006","journal-title":"Appl Biochem Biotechnol"},{"key":"10.1016\/j.biologicals.2017.05.002_bib28","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.procbio.2007.05.022","article-title":"Activity of recombinant GST in Escherichia coli grown on glucose and glycerol","volume":"42","author":"Hansen","year":"2007","journal-title":"Process Biochem"},{"key":"10.1016\/j.biologicals.2017.05.002_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1574-6976.1996.tb00255.x","article-title":"Flux analysis and control of the central metabolic pathways in Escherichia coli","volume":"19","author":"Holms","year":"1996","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.biologicals.2017.05.002_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-152828-7.50004-4","article-title":"The central metabolic pathways of Escherichia coli: relationship between flux and control at a branch point, efficiency of conversion to biomass, and excretion of acetate","volume":"28","author":"Holms","year":"1986","journal-title":"Curr Top Cell Regul"},{"key":"10.1016\/j.biologicals.2017.05.002_bib31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1472-765X.2009.02694.x","article-title":"Effects of feeding and induction strategy on the production of BmR1 antigen in recombinant E. coli","volume":"49","author":"Norsyahida","year":"2009","journal-title":"Lett Appl Microbiol"},{"key":"10.1016\/j.biologicals.2017.05.002_bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.14429\/dsj.59.1501","article-title":"High yield production of heterologous proteins with Escherichia coli","volume":"59","author":"Tripathi","year":"2009","journal-title":"Def Sci J"},{"key":"10.1016\/j.biologicals.2017.05.002_bib33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00449-005-0414-4","article-title":"Evaluation of the effects and interactions of mixing and oxygen transfer on the production of Fab' antibody fragments in Escherichia coli fermentation with gas blending","volume":"27","author":"Garcia-Arrazola","year":"2005","journal-title":"Bioprocess Biosyst Eng"},{"key":"10.1016\/j.biologicals.2017.05.002_bib34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/(SICI)1097-0290(19981105)60:3<271::AID-BIT1>3.0.CO;2-E","article-title":"Effect of post-induction nutrient feeding strategies on the production of bioadhesive protein in Escherichia coli","volume":"60","author":"Wong","year":"1998","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.biologicals.2017.05.002_bib35","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s10529-014-1526-1","article-title":"A\u00a0strategy for fusion expression and preparation of functional glucagon-like peptide-1 (GLP-1) analogue by introducing an enterokinase cleavage site","volume":"36","author":"Liu","year":"2014","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.biologicals.2017.05.002_bib36","doi-asserted-by":"crossref","first-page":"e0116805","DOI":"10.1371\/journal.pone.0116805","article-title":"In\u00a0vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products","volume":"10","author":"Liao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biologicals.2017.05.002_bib37","unstructured":"FDA, Guidance for industry. Genotoxic and carcinogenic impurities in drug substances and products, 2008."},{"key":"10.1016\/j.biologicals.2017.05.002_bib38","series-title":"EMEA Guideline on the limits of genotoxic impurities","author":"EMEA","year":"2006"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104510561730060X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104510561730060X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T02:26:30Z","timestamp":1569378390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104510561730060X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":38,"alternative-id":["S104510561730060X"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2017.05.002","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microbial expression of Exendin-4 analog and its efficacy in mice model","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2017.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}